DiaMedica Therapeutics Inc

NASDAQ DMAC

Data sourced from iex and EODHD
Download Data

DiaMedica Therapeutics Inc Debt to Tangible Net Worth Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2020: 28.10%

DiaMedica Therapeutics Inc Debt to Tangible Net Worth Ratio 1 year YoY Change (%) is 28.10% for the Trailing 12 Months (TTM) ending March 31, 2020. The debt to tangible net worth ratio measures the level of debt relative to a company's tangible net worth. It is calculated by dividing total debt by the difference between shareholders' equity and intangible assets (such as goodwill). This ratio provides insights into the company's financial leverage, excluding intangible assets. A higher ratio suggests a higher level of debt burden in relation to tangible net worth. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • DiaMedica Therapeutics Inc Debt to Tangible Net Worth Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.00, a 28.10% change year over year.
NASDAQ: DMAC

DiaMedica Therapeutics Inc

CEO Mr. Dietrich John Pauls MBA
IPO Date Jan. 4, 2008
Location United States
Headquarters Two Carlson Parkway, Minneapolis, MN, United States, 55447
Employees 18
Sector Healthcare
Industry Biotechnology
Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Similar companies

MIST

Milestone Pharmaceuticals Inc

NA

NA

CNTA

Centessa Pharmaceuticals PLC ADR

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email